The European Commission today closed its ongoing preliminary investigation into Edwards Lifesciences’ practices without a finding of any wrongdoing on Edwards’ part. Edwards is grateful for the Commission’s thorough review and for the constructive collaboration throughout.
The Commission’s announcement follows the withdrawal of Edwards’ Global Unilateral Pro-Innovation Policy (“UPIP”). Edwards removed the UPIP from its website in connection with the Commission’s investigation, with a view to providing clarity in that context.
As the pioneer in structural heart innovation, Edwards is dedicated to addressing the unmet needs of structural heart patients worldwide through the development of breakthrough therapies, as well as to clinical study, research, and evidence generation. Edwards is committed to innovation and to the innovative process in collaboration with its physician partners. Edwards values its longstanding collaborations with physicians and looks forward to continuing these relationships and exploring new opportunities.
Edwards is committed to free and fair competition in the structural heart space and to the advancements made possible by innovation competition and the protection of intellectual property rights and trade secrets. As such, Edwards continues to take IP and trade secret protections very seriously and will take all appropriate steps to ensure that trade secrets and other commercially sensitive information are not leaked to competitors.
For inquiries regarding the above, please contact media@edwards.com.
